抗真菌药在体外膜肺氧合患者中的剂量调整.

Extracorporeal membrane oxygenation（ ECMO） is a technique that saves patients with severe heart and lung failure through long-term cardiopulmonary support. As an important risk factor for invasive fungal infection, the application of ECMO will also increase the mortality of patients with invasive fungal infection. Due to the extracorporeal circulation circuit, the pharmacokinetics（ PK）/pharmacodynamics（ PD） of antifungal drugs in ECMO patients have undergone major changes. This article summarizes the possible influencing factors of the PK/PD of drugs in ECMO patients, and introduces the characteristics of ECMO patients, the adjustment of antifungal treatment regimens and related population PK and physiological PK modeling studies, with the aim of providing reference for dosing application in similar patients. In the absence of prospective, multi center randomized controlled studies, therapeutic drug monitoring of antifungal drugs in ECMO patients is a more reasonable option [ABSTRACT FROM AUTHOR]